Status:
TERMINATED
Neoadjuvant Celecoxib and Capecitabine Combined With Pelvic Irradiation in Treating Patients With Stage II or Stage III Adenocarcinoma (Cancer) of the Rectum
Lead Sponsor:
Alliance for Clinical Trials in Oncology
Collaborating Sponsors:
National Cancer Institute (NCI)
Conditions:
Colorectal Cancer
Eligibility:
All Genders
18+ years
Phase:
PHASE2
Brief Summary
RATIONALE: Celecoxib may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs used in chemotherapy, such as capecitabine, work in different ways to stop tumor cells...
Detailed Description
OBJECTIVES: Primary * Determine the pathological complete response rate in patients with stage II or III adenocarcinoma of the rectum treated with neoadjuvant celecoxib and capecitabine in combinati...
Eligibility Criteria
Inclusion
- DISEASE CHARACTERISTICS:
- Histologically confirmed rectal adenocarcinoma
- Clinical stage T3, N0, M0 OR any T, N1-3, M0 disease
- Treatment with neoadjuvant chemotherapy and pelvic radiotherapy is indicated
- All disease must be encompassable within standard pelvic radiotherapy fields
- Distal border of the tumor must be at or below\* the peritoneal reflection, defined as within 12 cm of the anal verge by endoscopy NOTE: \*If a portion of the tumor is below the peritoneal reflection at the time of surgery, patients are eligible regardless of the distance of the tumor determined at endoscopy
- Tumor must be determined to be clinically resectable
- Tumor may not be clinically fixed
- Negative margins by routine examination of an unanesthetized patient
- Transmural penetration of tumor through the muscularis propria by CT scan, endorectal ultrasound, or MRI
- No distant metastatic disease
- No evidence of tumor outside the pelvis, including any of the following:
- Metastatic inguinal lymphadenopathy
- Peritoneal seeding
- Liver metastases
- PATIENT CHARACTERISTICS:
- Age
- 18 and over
- Performance status
- ECOG 0-1
- Life expectancy
- At least 6 months
- Hematopoietic
- Absolute neutrophil count ≥ 1,500/mm\^3
- Platelet count ≥ 100,000/mm\^3
- Hepatic
- Bilirubin ≤ upper limit of normal (ULN)
- AST ≤ 3 times ULN
- Alkaline phosphatase ≤ 4 times ULN if AST \< ULN
- Renal
- Creatinine clearance ≥ 30 mL/min
- No renal impairment
- Cardiovascular
- No congestive heart failure
- No symptomatic coronary artery disease
- No uncontrolled cardiac arrhythmias
- No myocardial infarction
- No history of transient ischemic attacks or stroke
- No other clinically significant cardiac disease
- Gastrointestinal
- No bleeding peptic ulcer disease within the past 12 months
- No lack of physical integrity of the upper gastrointestinal tract
- No malabsorption syndrome
- No active inflammatory bowel disease
- Must be able to swallow study drugs
- Other
- No dihydropyrimidine dehydrogenase deficiency
- No history of uncontrolled seizures
- No CNS disorders
- No clinically significant psychiatric illness that would preclude study compliance or giving informed consent
- No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
- No known sensitivity to NSAIDs, sulfonamides, or aspirin
- No other serious medical illness that would preclude study treatment
- No other conditions that would preclude study participation
- Must be able to tolerate major surgery that may include abdominal-perineal resection
- Not pregnant or nursing
- Negative pregnancy test
- Fertile patients must use effective contraception during and for 30 days after study treatment
- PRIOR CONCURRENT THERAPY:
- Biologic therapy
- Not specified
- Chemotherapy
- See Disease Characteristics
- No prior systemic anticancer chemotherapy
- Endocrine therapy
- Not specified
- Radiotherapy
- See Disease Characteristics
- No prior radiotherapy to the pelvis
- Surgery
- See Disease Characteristics
- More than 3 weeks since prior major surgery and recovered
- Other
- At least 7 days since prior nonsteroidal anti-inflammatory drugs (NSAIDs), including aspirin
- No other concurrent investigational drugs
- No other concurrent anticancer treatment
- No concurrent NSAIDs
- No concurrent primary prophylactic therapy for hand-foot syndrome
- No concurrent loperamide prophylaxis for diarrhea
- No concurrent sorivudine or brivudine
Exclusion
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 1 2010
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00081224
Start Date
December 1 2004
End Date
November 1 2010
Last Update
December 15 2016
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.